Based on its recent analysis of the nuclear cardiology market, Frost & Sullivan recognizes Siemens Healthcare with the 2011 North America Frost & Sullivan Product Differentiation Excellence of the Year Award for its IQ-SPECT, a distinct imaging solution. This product not only offers high-quality imaging by achieving maximum counts, but does so in the quarter amount of time taken by conventional single photon emission computed tomography (SPECT) systems and with less radiation.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/frostsullivan/53611/
Corindus Vascular Robotics, a leading developer of precision vascular robotics, today announced FDA 510(k) clearance has been granted for the CorPath 200 System to be used in percutaneous coronary interventions (PCI). The technology is now approved in the United States to assist interventional cardiologists in performing PCI, a procedure to restore blood flow to blocked arteries in patients with coronary artery disease (CAD).
“We are pleased to have received clearance from the FDA for the world’s first system designed for robotic-assisted PCI procedures,” said David M. Handler, President and CEO of Corindus Vascular Robotics. “This is an important milestone for interventional cardiology as we take the next step in transforming the way these procedures are performed in the future. The CorPath System offers hospitals the opportunity to bring robotic-assisted technology benefits to their coronary patients and their physicians.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/57343-corindus-vascular-robotics-wins-fda-510k-clearance-for-corpath-200-system
The new BUENA SALUD™ series of books (the phrase translates to “Good Health”) launches today with titles on heart health (foreword by CEO of the American College of Cardiology) and diabetes (foreword by CEO of the American Diabetes Association). Written by Dr. Jane L. Delgado, President and CEO of the National Alliance for Hispanic Health, the book series is the first ever devoted to the health experiences of a growing Hispanic readership. The guides feature real-life stories and deliver health information and cutting-edge medical advances for individual diseases and conditions in a warm and conversational tone. The books are published simultaneously in English and Spanish. These authoritative and accessible guides each feature a “10-Point Program for Health,” facts and information in a useful Q&A format, and key questions to ask health providers. In a just published feature review, the Library Journal gave a starred review and called the BUENA SALUD™ series “essential reading” and “a crucial addition to any consumer health collection.”
Hoy se lanza lanuevaseriedelibros titulada BUENASALUD™,la cual trata sobre temas como la salud del corazón(prólogo por el CEOdelaAmerican College of Cardiology) y ladiabetes(prólogo por el CEOde laAsociaciónAmericanade Diabetes). Escritaporla Dra. JaneL.Delgado, Presidenta yDirectora Ejecutiva delaAlianzaNacionalpara laSalud de los Hispanos, esta serie de librosesla primera dedicada alas experienciasde saluddel creciente número de lectoreshispanos.Lasguíascuentanhistoriasde la vida realy ofreceninformaciónsobrela salud y los últimos avancesmédicospara enfermedadesy condiciones individuales,en untonocálidoyde conversación.
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and haemodynamic monitoring, announced the results of a pivotal clinical study of high-risk surgical patients with severe aortic stenosis treated in Cohort A of The PARTNER Trial. These data demonstrate that the study achieved its primary endpoint at one year, concluding that survival of patients treated with the Edwards SAPIEN transcatheter aortic valve was equivalent to those treated with surgical aortic valve replacement. The data were presented at the American College of Cardiology’s (ACC) 60th Annual Scientific Session & Expo in New Orleans, LA, USA.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/edwardslifesciences/48895/
According to a new report, How Can We Avoid a Stroke Crisis in the Asia-Pacific Region?, urgent coordinated action is needed to avoid millions of preventable strokes, which leave many patients who have atrial fibrillation (AF) both mentally and physically disabled, or dead, every year.
The report, launched today during the 18th Asian Pacific Congress of Cardiology (APCC) by Action for Stroke Prevention, a group of health experts from across the globe, proposes urgent measures to prevent stroke in Asia-Pacific patients with AF, the most common, sustained abnormal heart rhythm and a major cause of stroke. The report’s recommendations are endorsed by 32 leading Asia-Pacific and other global medical societies and patient organizations, reinforcing and recognizing the need for a call to action.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/strikeoutstroke/48909/
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from two Phase 2 trials with SAR236553/REGN727, an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), were presented at the American College of Cardiology’s (ACC) 61st Annual Scientific Meeting in Chicago.
The data showed that treatment with SAR236553/REGN727 over 8 to 12 weeks significantly reduced mean low-density lipoprotein-cholesterol (LDL-C, or “bad” cholesterol) by 40% to 72% in patients with elevated LDL-C on stable dose of statins.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55299-sanofi-regeneron-pharmaceuticals-lipid-lowering-medications-pcsk9-antibody
